Publications
Export 20 results:
Filters: Author is Golde, Todd E [Clear All Filters]
Targeting Notch in oncology: the path forward. Nat Rev Drug Discov, 20(2), 125-144. presented at the 2021 02. doi:10.1038/s41573-020-00091-3
. (2021). Targeting Notch in oncology: the path forward. Nat Rev Drug Discov, 20(2), 125-144. presented at the 2021 02. doi:10.1038/s41573-020-00091-3
. (2021). CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells. Frontiers in Immunology, 11. Retrieved from https://doi.org/10.3389/fimmu.2020.00735
. (2020). y-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse y-secretase modulators do not. Alzheimer{\textquotesingle}s Research {&} Therapy, 12. Retrieved from https://doi.org/10.1186/s13195-020-00622-5
. (2020). Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells. Journal of Biological Chemistry, 294, 11276–11285. Retrieved from https://doi.org/10.1074/jbc.ra119.008041
. (2019). Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells. J Biol Chem, 294(29), 11276-11285. presented at the 2019 07 19. doi:10.1074/jbc.RA119.008041
. (2019). Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Frontiers in Immunology, 9. Retrieved from https://doi.org/10.3389/fimmu.2018.01288
. (2018). . (2018).
Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29. Mol Immunol, 99, 191-198. presented at the 2018 07. doi:10.1016/j.molimm.2018.05.002
. (2018). Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29. Molecular Immunology, 99, 191–198. Retrieved from https://doi.org/10.1016/j.molimm.2018.05.002
. (2018). γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.. {EMBO} Molecular Medicine, 9, 950–966. presented at the may. Retrieved from https://doi.org/10.15252/emmm.201607265
. (2017). Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4(+) T Cells. Front Immunol, 5, 54. presented at the 2014.
. (2014). NOTCH1 Can Initiate NF-κB Activation via Cytosolic Interactions with Components of the T Cell Signalosome.. Front Immunol, 5, 249. presented at the 2014.
. (2014). Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med, 210(7), 1311-29. presented at the 2013 Jul 1.
. (2013). Transient pharmacologic lowering of Aß production prior to deposition results in sustained reduction of amyloid plaque pathology.. Molecular neurodegeneration, 7(1), 39. presented at the 2012 Aug 14.
. (2012). Notch regulates cytolytic effector function in CD8+ T cells. Journal of immunology (Baltimore, Md. : 1950), 182(6), 3380-9. presented at the 2009 Mar 15.
. (2009). Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood, 113(8), 1689-98. presented at the 2009 Feb 19.
. (2009). Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood, 112(5), 1813-21. presented at the 2008 Sep 1.
. (2008). Notch1 augments NF-kappaB activity by facilitating its nuclear retention. The EMBO journal, 25(1), 129-38. presented at the 2006 Jan 11.
. (2006). Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nature immunology, 6(7), 680-8. presented at the 2005 Jul.
. (2005).
Veterinary and Animal Sciences